Srdjan Stankovic
Acadia Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Schizophrenia research and treatment, Parkinson's Disease Mechanisms and Treatments, Alzheimer's disease research and treatments, Attention Deficit Hyperactivity Disorder, Cholinesterase and Neurodegenerative Diseases
Most-Cited Works
- → Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study(2018)187 cited
- → Trial of Pimavanserin in Dementia-Related Psychosis(2021)127 cited
- → Pimavanserin: Potential Treatment For Dementia-Related Psychosis(2018)83 cited
- → Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms(2019)39 cited
- → Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis(2020)20 cited
- → Trofinetide for the treatment of Rett syndrome: an open-label study in girls 2 to 4 years of age (P13-9.005)(2023)5 cited
- → Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia(2022)5 cited
- → T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT(2020)1 cited
- → Pimavanserin for the Treatment of Alzheimer’s Disease Psychosis: An Evaluation of the Clinical Importance of Efficacy Results(2022)1 cited
- Development of the disease and fatal outcome in a patient with Bernard-Soulier syndrome(2009)